Table 3

Central macular thickness after intravitreal injection in the IVB and IVB/IVF groups

ParameterTotalGroupDifference95%CIP values
IVBIVB/IVFLowerUpper
Baseline
 Mean±SD528±100511±96543±102−33−94300.558*
Month 3
 Mean±SD405±109439±112373±1009551139<0.001†
Change (baseline—3)
 Mean±SD−123±88−72±83−170±649851144<0.001*
 P-within‡0.006<0.001
Month 6
 Mean±SD429±141509±120356±119192136248<0.001†
Change (baseline—6)
 Mean±SD−100±1360±87−191±105191129253<0.001*
 P-within‡>0.99<0.001
  • *Based on t-test.

  • †Adjusted for the baseline, based on analysis of covariance.

  • ‡Based on linear mixed model, multiple comparison considered by Bonferroni method.

  • IVB, intravitreal injection of bevacizumab; IVB/IVF, intravitreal injection of both bevacizumab and fasudil.